[{"id":"27145ff7-4899-4e16-a0c3-153894083c4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05475210","created_at":"2022-07-26T17:10:16.861Z","updated_at":"2024-07-02T16:35:15.078Z","phase":"Phase 1","brief_title":"177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors","source_id_and_acronym":"NCT05475210","lead_sponsor":"Molecular Targeting Technologies, Inc.","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-EBTATE"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 06/18/2022","start_date":" 06/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-03-13"},{"id":"81498a4c-038d-488e-857c-348cb81a2810","acronym":"","url":"https://clinicaltrials.gov/study/NCT03478358","created_at":"2021-02-11T16:53:34.239Z","updated_at":"2024-07-02T16:36:04.680Z","phase":"Phase 1","brief_title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","source_id_and_acronym":"NCT03478358","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • 177Lu-EBTATE • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2017","start_date":" 04/30/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-08-31"},{"id":"4ab43aab-4ba9-4d0d-a21f-698d579c94b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03308682","created_at":"2021-02-11T16:53:26.503Z","updated_at":"2024-07-02T16:37:17.185Z","phase":"Phase 1","brief_title":"177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","source_id_and_acronym":"NCT03308682","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-EBTATE"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2017","start_date":" 04/30/2017","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2017-10-12"}]